Strong therapeutic potential of γ-secretase inhibitor MRK003 for CD44-high and CD133-low glioblastoma initiating cells

Shingo Tanaka, Mitsutoshi Nakada, Daisuke Yamada, Ichiro Nakano, Tomoki Todo, Yasushi Ino, Takayuki Hoshii, Yuko Tadokoro, Kumiko Ohta, Mohamed A.E. Ali, Yutaka Hayashi, Jun ichiro Hamada, Atsushi Hirao

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The Notch signal regulates both cell viability and apoptosis, and maintains stemness of various cancers including glioblastoma (GBM). Although Notch signal inhibition may be an effective strategy in treating GBM initiating cells (GICs), its applicability to the different subtypes of GBM remains unclear. Here, we analyzed the effectiveness of MRK003, a preclinical γ-secretase inhibitor, on GICs. Nine patient-derived GICs were treated by MRK003, and its efficacy on cell viability, apoptosis, sphere forming ability and Akt expression level which might be related to Notch downstream and be greatly important signals in GBM was evaluated. MRK003 suppressed viability and sphere-formation ability, and induced apoptosis in all GICs in varying doses of MRK003. Based on their sensitivities to MRK003, the nine GICs were divided into “relatively sensitive” and “relatively resistant” GICs. Sensitivity to MRK003 was associated with its inhibitory effect on Akt pathway. Transgenic expression of the myristoylated Akt vector in relatively sensitive GICs partially rescued the effect of MRK003, suggesting that the effect of MRK003 was, at least in part, mediated through inhibition of the Akt pathway. These GICs were differentiated by the expression of CD44 and CD133 with flow cytometric analysis. The relatively sensitive GICs are CD44-high and CD133-low. The IC50 of MRK003 in a set of GICs exhibited a negative correlation with CD44 and positive correlation with CD133. Collectively, MRK003 is partially mediated by the Akt pathway and has strong therapeutic potential for CD44-high and CD133-low GICs.

Original languageEnglish
Pages (from-to)239-250
Number of pages12
JournalJournal of neuro-oncology
Volume121
Issue number2
DOIs
Publication statusPublished - Jan 1 2015
Externally publishedYes

Fingerprint

Amyloid Precursor Protein Secretases
Glioblastoma
Therapeutics
Apoptosis
Cell Survival
MRK 003
Inhibitory Concentration 50

Keywords

  • CD133
  • CD44
  • GBM initiating cells
  • Glioma
  • MRK003

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Strong therapeutic potential of γ-secretase inhibitor MRK003 for CD44-high and CD133-low glioblastoma initiating cells. / Tanaka, Shingo; Nakada, Mitsutoshi; Yamada, Daisuke; Nakano, Ichiro; Todo, Tomoki; Ino, Yasushi; Hoshii, Takayuki; Tadokoro, Yuko; Ohta, Kumiko; Ali, Mohamed A.E.; Hayashi, Yutaka; Hamada, Jun ichiro; Hirao, Atsushi.

In: Journal of neuro-oncology, Vol. 121, No. 2, 01.01.2015, p. 239-250.

Research output: Contribution to journalArticle

Tanaka, S, Nakada, M, Yamada, D, Nakano, I, Todo, T, Ino, Y, Hoshii, T, Tadokoro, Y, Ohta, K, Ali, MAE, Hayashi, Y, Hamada, JI & Hirao, A 2015, 'Strong therapeutic potential of γ-secretase inhibitor MRK003 for CD44-high and CD133-low glioblastoma initiating cells', Journal of neuro-oncology, vol. 121, no. 2, pp. 239-250. https://doi.org/10.1007/s11060-014-1630-z
Tanaka, Shingo ; Nakada, Mitsutoshi ; Yamada, Daisuke ; Nakano, Ichiro ; Todo, Tomoki ; Ino, Yasushi ; Hoshii, Takayuki ; Tadokoro, Yuko ; Ohta, Kumiko ; Ali, Mohamed A.E. ; Hayashi, Yutaka ; Hamada, Jun ichiro ; Hirao, Atsushi. / Strong therapeutic potential of γ-secretase inhibitor MRK003 for CD44-high and CD133-low glioblastoma initiating cells. In: Journal of neuro-oncology. 2015 ; Vol. 121, No. 2. pp. 239-250.
@article{304d8ec114dd460684dbccc56bdeac36,
title = "Strong therapeutic potential of γ-secretase inhibitor MRK003 for CD44-high and CD133-low glioblastoma initiating cells",
abstract = "The Notch signal regulates both cell viability and apoptosis, and maintains stemness of various cancers including glioblastoma (GBM). Although Notch signal inhibition may be an effective strategy in treating GBM initiating cells (GICs), its applicability to the different subtypes of GBM remains unclear. Here, we analyzed the effectiveness of MRK003, a preclinical γ-secretase inhibitor, on GICs. Nine patient-derived GICs were treated by MRK003, and its efficacy on cell viability, apoptosis, sphere forming ability and Akt expression level which might be related to Notch downstream and be greatly important signals in GBM was evaluated. MRK003 suppressed viability and sphere-formation ability, and induced apoptosis in all GICs in varying doses of MRK003. Based on their sensitivities to MRK003, the nine GICs were divided into “relatively sensitive” and “relatively resistant” GICs. Sensitivity to MRK003 was associated with its inhibitory effect on Akt pathway. Transgenic expression of the myristoylated Akt vector in relatively sensitive GICs partially rescued the effect of MRK003, suggesting that the effect of MRK003 was, at least in part, mediated through inhibition of the Akt pathway. These GICs were differentiated by the expression of CD44 and CD133 with flow cytometric analysis. The relatively sensitive GICs are CD44-high and CD133-low. The IC50 of MRK003 in a set of GICs exhibited a negative correlation with CD44 and positive correlation with CD133. Collectively, MRK003 is partially mediated by the Akt pathway and has strong therapeutic potential for CD44-high and CD133-low GICs.",
keywords = "CD133, CD44, GBM initiating cells, Glioma, MRK003",
author = "Shingo Tanaka and Mitsutoshi Nakada and Daisuke Yamada and Ichiro Nakano and Tomoki Todo and Yasushi Ino and Takayuki Hoshii and Yuko Tadokoro and Kumiko Ohta and Ali, {Mohamed A.E.} and Yutaka Hayashi and Hamada, {Jun ichiro} and Atsushi Hirao",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s11060-014-1630-z",
language = "English",
volume = "121",
pages = "239--250",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Strong therapeutic potential of γ-secretase inhibitor MRK003 for CD44-high and CD133-low glioblastoma initiating cells

AU - Tanaka, Shingo

AU - Nakada, Mitsutoshi

AU - Yamada, Daisuke

AU - Nakano, Ichiro

AU - Todo, Tomoki

AU - Ino, Yasushi

AU - Hoshii, Takayuki

AU - Tadokoro, Yuko

AU - Ohta, Kumiko

AU - Ali, Mohamed A.E.

AU - Hayashi, Yutaka

AU - Hamada, Jun ichiro

AU - Hirao, Atsushi

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The Notch signal regulates both cell viability and apoptosis, and maintains stemness of various cancers including glioblastoma (GBM). Although Notch signal inhibition may be an effective strategy in treating GBM initiating cells (GICs), its applicability to the different subtypes of GBM remains unclear. Here, we analyzed the effectiveness of MRK003, a preclinical γ-secretase inhibitor, on GICs. Nine patient-derived GICs were treated by MRK003, and its efficacy on cell viability, apoptosis, sphere forming ability and Akt expression level which might be related to Notch downstream and be greatly important signals in GBM was evaluated. MRK003 suppressed viability and sphere-formation ability, and induced apoptosis in all GICs in varying doses of MRK003. Based on their sensitivities to MRK003, the nine GICs were divided into “relatively sensitive” and “relatively resistant” GICs. Sensitivity to MRK003 was associated with its inhibitory effect on Akt pathway. Transgenic expression of the myristoylated Akt vector in relatively sensitive GICs partially rescued the effect of MRK003, suggesting that the effect of MRK003 was, at least in part, mediated through inhibition of the Akt pathway. These GICs were differentiated by the expression of CD44 and CD133 with flow cytometric analysis. The relatively sensitive GICs are CD44-high and CD133-low. The IC50 of MRK003 in a set of GICs exhibited a negative correlation with CD44 and positive correlation with CD133. Collectively, MRK003 is partially mediated by the Akt pathway and has strong therapeutic potential for CD44-high and CD133-low GICs.

AB - The Notch signal regulates both cell viability and apoptosis, and maintains stemness of various cancers including glioblastoma (GBM). Although Notch signal inhibition may be an effective strategy in treating GBM initiating cells (GICs), its applicability to the different subtypes of GBM remains unclear. Here, we analyzed the effectiveness of MRK003, a preclinical γ-secretase inhibitor, on GICs. Nine patient-derived GICs were treated by MRK003, and its efficacy on cell viability, apoptosis, sphere forming ability and Akt expression level which might be related to Notch downstream and be greatly important signals in GBM was evaluated. MRK003 suppressed viability and sphere-formation ability, and induced apoptosis in all GICs in varying doses of MRK003. Based on their sensitivities to MRK003, the nine GICs were divided into “relatively sensitive” and “relatively resistant” GICs. Sensitivity to MRK003 was associated with its inhibitory effect on Akt pathway. Transgenic expression of the myristoylated Akt vector in relatively sensitive GICs partially rescued the effect of MRK003, suggesting that the effect of MRK003 was, at least in part, mediated through inhibition of the Akt pathway. These GICs were differentiated by the expression of CD44 and CD133 with flow cytometric analysis. The relatively sensitive GICs are CD44-high and CD133-low. The IC50 of MRK003 in a set of GICs exhibited a negative correlation with CD44 and positive correlation with CD133. Collectively, MRK003 is partially mediated by the Akt pathway and has strong therapeutic potential for CD44-high and CD133-low GICs.

KW - CD133

KW - CD44

KW - GBM initiating cells

KW - Glioma

KW - MRK003

UR - http://www.scopus.com/inward/record.url?scp=84925497798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925497798&partnerID=8YFLogxK

U2 - 10.1007/s11060-014-1630-z

DO - 10.1007/s11060-014-1630-z

M3 - Article

C2 - 25293440

AN - SCOPUS:84925497798

VL - 121

SP - 239

EP - 250

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -